Zobrazeno 1 - 10
of 86
pro vyhledávání: '"Daniela Melchiorri"'
Autor:
Simone Lista, Bruno P. Imbimbo, Margherita Grasso, Annamaria Fidilio, Enzo Emanuele, Piercarlo Minoretti, Susana López-Ortiz, Juan Martín-Hernández, Audrey Gabelle, Giuseppe Caruso, Marco Malaguti, Daniela Melchiorri, Alejandro Santos-Lozano, Camillo Imbimbo, Michael T. Heneka, Filippo Caraci
Publikováno v:
Journal of Neuroinflammation, Vol 21, Iss 1, Pp 1-24 (2024)
Abstract Background Recent trials of anti-amyloid-β (Aβ) monoclonal antibodies, including lecanemab and donanemab, in early Alzheimer disease (AD) showed that these drugs have limited clinical benefits and their use comes with a significant risk of
Externí odkaz:
https://doaj.org/article/65c828dd2d264d94a3f2ad4890c2bcd1
Autor:
Martin Šíma, Andrea Laslop, John Joseph Borg, Silvester Poništ, Daniela Melchiorri, František Dráfi
Publikováno v:
Frontiers in Pharmacology, Vol 14 (2023)
Externí odkaz:
https://doaj.org/article/fda59456736f44d0bc1d7376506f04a1
Publikováno v:
Frontiers in Pharmacology, Vol 14 (2023)
Despite extensive research, no disease-modifying therapeutic option, able to prevent, cure or halt the progression of Alzheimer’s disease [AD], is currently available. AD, a devastating neurodegenerative pathology leading to dementia and death, is
Externí odkaz:
https://doaj.org/article/535ca8e1a41043d882cffa3584c77f33
Autor:
Daniela Melchiorri, Jonas Bergh, Francesco Pignatti, Didier Meulendijks, Paula Hennik, Bjorg Bolstad, Luca Moscetti, Jorge Camarero, Filip Josephson, Maja Sommerfelt Grønvold, Jan Sjoberg, Mihaela Botezatu, Jorn Mulder, Ana Trullas Jimeno, Nikolaos Zafiropoulos, Harald Enzmann
Publikováno v:
ESMO Open, Vol 5, Iss 4 (2020)
The therapeutic landscape in the treatment of advanced/metastatic renal cell cancer has evolved over the last 2 years with the advent of immune checkpoint inhibitors. In 2018 and 2019, marketing authorisations valid throughout the European Union were
Externí odkaz:
https://doaj.org/article/7a7953d10b004678ab44dca70ec3f5f2
Autor:
Beatriz Florez, Greg Markey, Mariapaola Caleno, Odoardo Maria Olimpieri, Daniela Melchiorri, Doris Johanna Hovgaard, Sinan Bardakci Sarac, Karri Penttilä, Tuomo Lapveteläinen, Jonas Bergh
Publikováno v:
ESMO Open, Vol 4, Iss 5 (2019)
On 21 November 2016, the European Commission issued a marketing authorisation valid throughout the European Union for ixazomib in combination with lenalidomide and dexamethasone for the treatment of adult patients with multiple myeloma who have recei
Externí odkaz:
https://doaj.org/article/299d78087e884913bdad06e045b92d29
Autor:
Francesco Matrisciano, Carla L Busceti, Domenico Bucci, Rosamaria Orlando, Alessandra Caruso, Gemma Molinaro, Irene Cappuccio, Barbara Riozzi, Roberto Gradini, Marta Motolese, Filippo Caraci, Agata Copani, Sergio Scaccianoce, Daniela Melchiorri, Valeria Bruno, Giuseppe Battaglia, Ferdinando Nicoletti
Publikováno v:
PLoS ONE, Vol 6, Iss 1, p e16447 (2011)
The identification of mechanisms that mediate stress-induced hippocampal damage may shed new light into the pathophysiology of depressive disorders and provide new targets for therapeutic intervention. We focused on the secreted glycoprotein Dickkopf
Externí odkaz:
https://doaj.org/article/f7bf3abcdb084a838fe8882651ebf351
Autor:
Jonas Bergh, Jorn Mulder, Mihaela Botezatu, Luca Moscetti, Filip Josephson, Ana Trullas Jimeno, Nikolaos Zafiropoulos, Paula van Hennik, Jan Sjöberg, Daniela Melchiorri, Harald Enzmann, Didier Meulendijks, Francesco Pignatti, Maja Sommerfelt Grønvold, Bjorg Bolstad, Jorge Camarero
Publikováno v:
ESMO Open
ESMO Open, Vol 5, Iss 4 (2020)
ESMO Open, Vol 5, Iss 4 (2020)
The therapeutic landscape in the treatment of advanced/metastatic renal cell cancer has evolved over the last 2 years with the advent of immune checkpoint inhibitors. In 2018 and 2019, marketing authorisations valid throughout the European Union were
Autor:
Francesco Pignatti, Sahra Ali, Filip Josephson, Jonas Bergh, Daniela Melchiorri, Odoardo Olimpier, Kyriaki Tzogani, Jorge Camarero, Christian Gisselbrecht, Dominik Karres, Alexandre Moreau
On November 15, 2018, the Committee for Medicinal Products for Human Use (CHMP) recommended the extension of indication for blinatumomab to include the treatment of adults with minimal residual disease (MRD) positive B‐cell precursor acute lymphobl
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e55e9fecb2d0f0c491251cf404082253
http://hdl.handle.net/11573/1616025
http://hdl.handle.net/11573/1616025
Autor:
Sinan B. Sarac, Jonas Bergh, Tomas Salmonson, Christian Gisselbrecht, Greg Markey, Karri Penttilä, Kyriaki Tzogani, Mariapaola Caleno, Francesco Pignatti, Doris Hovgaard, Daniela Melchiorri, Tuomo Lapveteläinen, Odoardo Maria Olimpieri, Beatriz Florez
Publikováno v:
ESMO Open
ESMO Open, Vol 4, Iss 5 (2019)
ESMO Open, Vol 4, Iss 5 (2019)
On 21 November 2016, the European Commission issued a marketing authorisation valid throughout the European Union for ixazomib in combination with lenalidomide and dexamethasone for the treatment of adult patients with multiple myeloma who have recei